A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult Participants

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 14, 2017

Primary Completion Date

May 19, 2017

Study Completion Date

May 19, 2017

Conditions

Healthy

Interventions

DRUG

Darunavir/Cobicistat

Participants will receive a FDC tablet of darunavir 800 mg and cobicistat 150 mg orally in the morning of Day 1.

Trial Locations (1)

Souseikai Hakata Clinic, Fukuoka